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Abstract: Alzheimer’s disease (AD) is a chronic neurodegenerative disorder characterized 
by a progressive loss of cognitive and functional abilities associated with various behavioral 
disturbances. Its impact on public health and society as a whole is devastating. Slowing of the 
cognitive impairment, and improvements in disease duration, self-sufﬁ  ciency and behavioral 
disturbances represent the best outcomes of pharmacologic therapy. Cholinesterase inhibitors 
(ChE-I) have been shown to be effective in treating the cognitive, behavioral, and functional 
deﬁ  cits of AD. Rivastigmine is a dual inhibitor of both acetylcholine esterase (AChE) and 
butyrylcholinesterase (BuChE), enzymes involved in the hydrolysis of acetylcholine. Although 
this drug has been shown to be beneﬁ  cial in patients with AD, its beneﬁ  ts are limited and their 
long-term effectiveness has not been well demonstrated.
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Introduction
Dementia of Alzheimer’s type (AD) (McKhann et al 1984) is a chronic neurode-
generative disorder. It is characterized by an insidious onset and a progressive loss 
of cognitive and functional abilities, associated with various degrees of behavioral 
disturbances, and progressively leads to total dependency.
AD is the most common form of dementia, accounting for 50%–60% of all cases. 
The prevalence of dementia is below 1% in individuals aged 60–64 years, but shows 
an almost exponential increase with age, so that in people aged 85 years or older the 
prevalence in the western world is between 24% and 33% (Ferri et al 2005). Repre-
sentative data from developing countries are sparse, but about 60% of all patients with 
dementia are estimated to live in this part of the world. AD is very common and is thus 
a major public health problem. In 2001, more than 24 million people had dementia 
and, due to the probable increase in life expectancy (Ferri et al 2005), this number is 
expected to double every 20 years and reach 81 million in 2040.
Since AD has become a major health and economic burden to society, many efforts 
are being made to develop a therapeutic strategy to modify the natural history of this 
disease. Generally, AD has a mean duration of 6–10 years. The annual cognitive loss, 
measured with the Alzheimer’s Disease Assessment Scale Cognitive Subscale (ADAS-
Cog) (Rosen et al 1984), is 8–10 points, and with the Mini Mental Status Examina-
tion (MMSE) (Folstein et al 1975), 2–4 points; the Clinical Rating and Clinician’s 
Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus) (Schneider 
et al 1997) reports a 6-month decline of about 1.5%. Note that these scales are the ones 
most used in the assessment of cognitive disorders. Approximately 4–6 years elapse 
between AD patients’ total autonomy and total functional dependency. Behavioral 
disturbances are present in at least 90% of patients and, depending on environmental 
variables, with variable incidence at different stages, in different individuals and in 
the same patient at different times. Disease duration, leading to total dependency, can Therapeutics and Clinical Risk Management 2007:3(6) 1114
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stretch over many years and create unsatisfactory and poor 
quality of life, for patients, relatives and caregivers; therefore, 
the latter represents one of the most important outcomes for 
pharmacologic therapy.
Following the discovery of a substantial pre-synaptic 
cholinergic deﬁ  cit in AD brains 25 years ago, a large body of 
experimental data has been gathered to examine the nature, 
extent, and clinical signiﬁ  cance of this change. Several stud-
ies on AD have shown abnormalities of many neurotransmit-
ter systems (particularly glutamatergic changes), the most 
prominent of which is severe damage of the cholinergic 
system with a selective loss of pre-synaptic cholinergic 
neurons projecting to cerebral cortex and hippocampus, lead-
ing to the so-called “cholinergic hypothesis”. Thus, some of 
the symptoms of AD are thought to be due to a cholinergic 
deﬁ  cit, and this theory has led to several therapeutic attempts 
to restore cholinergic activity in the central nervous system 
(CNS). To date, the most successful approach involves the 
cholinesterase inhibitor (ChE-I), which increases the amount 
of acetylcholine in the neuronal synaptic cleft by inhibiting 
the enzyme responsible for its degradation, thus improving 
neuronal transmission; the more recent molecules are selec-
tive, acting at the central level, minimizing side effects. It 
has also been shown that in the AD patient’s brain there is a 
loss of glutamatergic pyramidal neurons, while the number 
of glutamate receptors is maintained (in particular N-metil-
D-aspartate [NMDA] receptor). Based on this evidence, the 
therapeutic use of glutamatergic-blocking molecules has 
been proposed.
Currently two classes of drugs, ChE-I and NMDA 
receptor antagonist, are recommended for the symptomatic 
treatment of AD, each targeting a different neurochemical 
component thought to underlie the condition. The cholines-
terase inhibitors (donepezil, rivastigmine, and galantamine) 
are widely recommended for the treatment of mild to mod-
erate AD (Davies and Maloney 1976; Doody et al 2001; 
Ballard 2002). In 2004, the ﬁ  rst NMDA receptor antagonist 
(memantine) was approved for the treatment of moderate 
to severe AD. These drugs were initially used to improve 
memory and cognition; subsequently, they were also tested 
for use in improving global status and the capacity to remain 
independent in order to reduce the need for admission to resi-
dential/nursing care and to improve caregiver health-related 
quality of life (QoL).
The Health Technology Assessment (HTA) (Loveman 
et al 2006) Programme recently published a study to provide 
an updated review of the best quality evidence for the clinical 
effectiveness and cost-effectiveness of donepezil, rivastigmine, 
and galantamine for mild to moderately severe AD. For mild 
to moderately severe AD, the results of the study suggested 
that all three treatments were beneﬁ  cial when assessed using 
cognitive outcome measures. Global outcome measures 
were positive for donepezil and rivastigmine, but mixed for 
galantamine. Results for measures of functioning were mixed 
for donepezil and rivastigmine, but positive for galantamine. 
Behavior and mood measures were mixed for donepezil 
and galantamine, but showed no beneﬁ  t for rivastigmine. 
For memantine, two published randomized controlled trials 
(RCTs) were included; in one of these trials the participants 
were already being treated with donepezil. The results suggest 
that memantine is beneﬁ  cial when assessed using functional 
and global measurements. The effect of memantine on cogni-
tive, behavioral, and mood outcomes is, however, less clear.
Moreover, the Cochrane Collaboration (Birks 2006) 
recently assessed the effects of donepezil, galantamine, 
and rivastigmine in people with mild, moderate, or severe 
dementia due to AD. The results of 10 randomized, double-
blind, placebo-controlled trials demonstrate that treatment 
for 6 months with donepezil, galantamine, or rivastigmine 
at the recommended dose for people with AD produced 
improvements in cognitive function of, on average, 2.7 points 
(95% CI –3.0 to –2.3, p.0.00001), ie, in the mid range of the 
70-point ADAS-Cog Scale. Study clinicians rated global 
clinical state more positively in treated patients. Beneﬁ  ts of 
treatment were also seen on measures of activities of daily 
living and behavior. The effects were similar for patients 
with severe dementia, although there is very little evidence 
from only two trials.
These therapeutic indications and the guidelines for treat-
ment (Davies and Maloney 1976; Ballard 2002) mainly derive 
from RCTs. Despite methodological doubts about the large 
clinical use of data derived from an experimental context, 
these indications are based on the only proven evidence of 
an effective use of pharmacologic therapy in dementia.
This review aims to explore the scientiﬁ  c evidence for the 
clinical use of rivastigmine for people suffering from mild 
to moderately severe AD. Potential beneﬁ  ts of rivastigmine 
will be demonstrated on measures of global functioning, 
cognition, function, behavior, and health-related QoL. To 
achieve this aim, a comprehensive assessment of cognitive 
and behavioral functions will be carried out using a set of 
standardized tests.
Assessment tools used
To determine the prognosis of an illness such as AD, in which 
there is a continuous neurodegenerative process, it is useful Therapeutics and Clinical Risk Management 2007:3(6) 1115
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to assess how rapidly the disease is progressing clinically and 
how severely the patient is being affected. In the past, AD 
severity was most often deﬁ  ned by the degree of cognitive 
impairment and global functioning and by the presence of 
behavioral disturbances. Standardized rating scales are com-
monly used to obtain such information and to assess the disease 
progress. In this regard, instruments such as ADAS-Cog and 
MMSE are used to provide a measure of cognitive impairment. 
However, it has also been afﬁ  rmed that the degree of functional 
impairment also reﬂ  ects AD severity. The Global Deterioration 
Scale (GDS) (Reisberg et al 1997) was designed speciﬁ  cally 
to evaluate AD severity by measuring cognitive and functional 
performance. In addition, scores on an instrument such as the 
Progressive Deterioration Scale (PDS) (Dejong et al 1989) also 
provide an index of disease severity; they reﬂ  ect the ability 
of the patient with AD to perform speciﬁ  c instrumental and 
basic activities of daily living, which become increasingly 
compromised as the disease progresses.
Cognitive function
ADAS-Cog is a primary instrument, speciﬁ  cally designed to 
assess cognitive functioning in AD, and proven to be valid 
and reliable. It assesses various cognitive abilities including 
attention, memory, orientation and language. The score range 
is 0–70, with higher scores indicating poorer functioning.
MMSE is in another scale for evaluating cognitive per-
formance. It assesses many cognitive abilities: orientation, 
immediate recall, attention and calculation, delayed recall, 
and language. The score range is from 0 (severe impairment) 
to 30 (normal).
Global assessment
CIBIC-Plus provides a global rating of patients’ functioning 
in four areas: general, cognitive, behavioral and activities of 
daily living. The CIBIC-Plus is based on interviews with both 
patients and caregivers. The score range is on a scale of 1–7, 
with 1 showing marked improvement, 7 marked worsening 
and 4 no change.
GDS is a global rating of overall dementia severity. It 
was developed to assess primary degenerative dementia and 
to delineate disease stages. The stages are scored from 1 (no 
cognitive decline) to 7 (severe cognitive decline).
Activities of daily living
PDS is a disease-speciﬁ  c measure of changes in 29 items of 
the activities of daily living. It is a 100-point bipolar visual 
analog scale, based on caregiver input, that measures the 
ability of patients to perform various activities of differing 
complexity; a higher score represents better functional 
ability. The interview is conducted with the caregiver.
Instrumental Activities of Daily Living (IADL, also called 
Lawton’s scale) was developed by Lawton and Brody in 1969. 
It consists of a very useful questionnaire for evaluating the 
subject’s ability to perform daily tasks governed by cogni-
tive functions (judgment, language, orientation, calculation, 
memory, planning). This scale focuses on complex activities 
important for independent living in the community. Activities 
include the ability to use the telephone, shop, prepare food, 
housekeep, and handle ﬁ  nances.
The Nurses’ Observation Scale for Geriatric Patients 
(NOSGER) (Spiegel et al 1991) is used to assess various 
cognitive functions and behavior related to activities of daily 
living (self-care, disturbing behavior, instrumental activities 
of daily living, memory, mood, and social behavior). The 
NOSGER questionnaire is completed by the next of kin or 
by the caregiver who has most contact with the patient.
Cholinesterases and cholinergic 
hypothesis in Alzheimer’s disease
Since Davies and Maloney (Bartus et al 1982) ﬁ  rst proposed 
the “cholinergic hypothesis”, a large body of evidence has 
been gathered to support the view that impairment of cholin-
ergic function is of central importance in the pathogenesis of 
AD (Whitehouse et al 1982; Katzman 1986; Gallagher et al 
1995; Kasa et al 1997; O’Brian et al 2001). In patients with 
AD, cholinergic neuronal loss is particularly noticeable in 
the neocortex and hippocampus. These areas of the brain are 
associated with learning and memory, executive functioning, 
behavior and emotional responses (Cummings 2000). Build-
ing upon these studies, a number of therapeutic approaches 
have been developed with the aim of enhancing cholinergic 
function, the most successful of which has been the use of 
cholinesterase inhibitors (ChE-I).
Experimental data support an interaction between cho-
linergic deﬁ  cits and the formation of amyloid plaques and 
neuroﬁ  brillary tangles. Further, in vitro modulation of the 
cholinergic system has a neuroprotective effect. Prelimi-
nary evidence supporting a neuroprotective effect of ChE-I 
derives from studies on human cells and rat brains and cells. 
In humans affected by AD, the muscarinic agonists modify 
the liquoral concentration of β-amyloid (Borroni et al 2001). 
In vitro studies demonstrate that acetylcholinesterase (ChE) 
has the capacity to stimulate β-amyloid aggregation and 
ﬁ  bril formation.
With regard to cholinesterases, acetyl cholinesterase 
(AChE) is located mainly in neurons and butyrylcholinesterase Therapeutics and Clinical Risk Management 2007:3(6) 1116
Annicchiarico et al
(BuChE) in glial cells. BuChE action is more general and 
less understood than AChE activity, which is mainly devoted 
to hydrolyzing acetylcholine. BuChE activity is detected in 
all CNS areas receiving cholinergic innervation. Although 
it represents only 10% of AChE activity in the normal brain, 
with disease progression BuChE increases by 40%–90% 
in the AD brain and AChE simultaneously decreases its 
activity by up to 45%. AChE and BuChE are present in 
several molecular isoforms and in normal brain globular 
forms of four (G4) catalytic units they are the most common, 
followed by one (G1). In the AD brain, the globular form 
G1 becomes predominant as the disease progresses and the 
G4 level declines, and some data suggest that BuChE, rather 
than AChE, action may be particularly relevant in subjects 
with moderate-severe dementia (Tasker et al 2005).
ChE-I were initially used to improve memory and 
cognition. Subsequently, they were tested for their efﬁ  cacy 
in other aspects of AD treatment: to improve functional level 
and patient’s and caregiver’s quality of life; and to modify 
behavioral and cognitive status in a clinically signiﬁ  cant 
way (Davies and Maloney 1976; Doody et al 2001; Ballard 
2002).
Rivastigmine
Rivastigmine tartrate is a carbamate pseudo irreversible 
inhibitor of AChE and BuChE, which selectively inhibits 
ChE-I in the CNS as demonstrated using cerebrospinal ﬂ  uid 
ChE activity, The pharmacokinetic and pharmacodynamic 
characteristics of rivastigmine are presented in Table 1.
Rivastigmine is prepared in capsules and solutions for 
oral administration. In healthy adults it is adsorbed rapidly 
after oral administration; in AD patients no difference in 
absorption was found with age. Taking rivastigmine with 
food slows absorption and increases tolerability, because the 
adverse gastrointestinal effects are associated with high plasma 
levels. Rivastigmine binds to both the esterasic and ionic sites 
of AChE, preventing the enzyme from metabolizing ACh, 
but is dissociated much more slowly than AChE (“pseudoir-
reversible” action). Rivastigmine is metabolized by AChE 
and BuChE at the synapse. Its elimination, which is mostly 
renal, is complete approximately 24 hour after administration 
(Williams et al 2003). Relevant pharmacokinetic drug–drug 
interactions are unlikely because rivastigmine has low protein 
binding and is not metabolized via the hepatic CYP system, 
as are the ChE-I donepezil and galantamine. No clinically 
signiﬁ  cant interactions with 22 classes of concomitant medica-
tions were found in pooled data from RCTs (Grossberg et al 
2000). Adverse effects in trials are mainly cholinomimetic 
gastrointestinal symptoms, predominantly in the titration 
phase. These effects include nausea (17%–48%), vomiting 
(16%–27%) and diarrhea (11%–17%), minimized by increas-
ing the dose slowly (every month) in clinical practice and 
taking with food. In clinical trials, the theoretical cholinomi-
metic risk of bradycardia, especially in elderly patients, was 
not demonstrated to have any signiﬁ  cant effect on cardiac 
function. A large meta-analysis of 16 randomized controlled 
trials documented the tolerability of AChE inhibitors (Lanctôt 
et al 2003). While the withdrawal rate due to adverse events 
was greater in the AChE inhibitor group than in the placebo 
groups, the rate was 14% in rivastigmine recipients; the cor-
responding rate for overall frequency of adverse events was 
12%. Direct comparative studies of donepezil and rivastigmine 
(Wilkinson et al 2002) reported tolerability ﬁ  ndings similar to 
those of the above meta-analysis; the double blind, random-
ized, comparative trial Exceed has been conducted. More 
patients treated with rivastigmine than with donepezil reported 
“any adverse event” during the 4- to 14-week titration phase 
(82.0% and 64.7%, respectively). The higher rate of adverse 
events in the rivastigmine group, compared with the donepe-
zil group, during the titration phase appeared to be driven by 
an increased rate of nausea (32.9% vs 15.2%) and vomiting 
(27.9% vs 5.8%). In the maintenance phase, weeks 17–104, 
adverse event rates in the two groups were similar (78.7% for 
the rivastigmine group and 76.9% for the donepezil group). 
Premature discontinuations due to adverse events were higher 
in the rivastigmine group during the titration phase (14.1% 
vs 7.0% for donepezil) but similar in the maintenance phase 
(17.9% vs 14.1% for donepezil). There were no differences 
between rivastigmine- and donepezil-treated patients with 
respect to number of serious adverse events (SAEs) and SAEs 
leading to discontinuation. Because the adverse events are 
associated with peak plasma levels, rivastigmine transdermal 
Table 1 Pharmacokinetic and pharmacodynamic characteristics of rivastigmine
Half-life pharmacokinetic  15 h  Half-life pharmacodynamic  10 h  Tmax 0.5–2  h
Bioavailability  36%  Protein binding  40%  Metabolism by CYP system  no
Elimination  renal  Dose starting  1.5 mg bid  Dose maximum  6 mg bid
Drug interaction  no  AChE G1  yes  AChE G4  yesTherapeutics and Clinical Risk Management 2007:3(6) 1117
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patches with better tolerability and equal bioavailability and 
efﬁ  cacy are in advanced development.
Efﬁ  cacy of rivastigmine
The efﬁ  cacy of rivastigmine in the symptomatic treatment of 
patients with mild to moderate AD has been demonstrated in 
several large, 6-month, double-blind, placebo-controlled trials. 
Furthermore, over the past few years data have emerged sug-
gesting that this agent may have long-term beneﬁ  ts. Available 
data on the use of rivastigmine are summarized below.
Short-term therapy
Four controlled double blind vs placebo studies for treatment 
duration ranging from 13 to 26 weeks have been conducted 
(Table 2). Participants included in all trials were classiﬁ  ed as 
having probable AD of mild to moderate severity. All studies 
had 3 treatment arms, comparing various dosage levels of 
rivastigmine with a placebo. Two trials (Corey-Bloom et al 
1998; Rosler et al 1999) had treatment groups with doses of 
1–4 and 6–12 mg/day (ﬂ  exible-dose studies) and one trial 
had doses of 4 and 6 mg/day (Agid et al 1998). By the end 
of the follow-up, the mean doses were similar in the two 
ﬂ  exible-dose studies: 3.7 and 10.4 mg/day for the two groups 
in one (Rosler et al 1999) and 3.5 and 9.7 mg/day in the two 
groups in another (Corey-Bloom et al 1998). The remaining 
trial (Forette et al 1999) compared the effects of a twice-daily 
regimen compared with a three-times daily regimen, giving 
average doses of 9.6 and 10.1 mg/day, respectively. The trials 
were all multicenter studies, with total sample sizes ranging 
from 114 to 725 participants. The studies demonstrated a 
statistically signiﬁ  cant difference between drug and placebo 
on neuropsychological scales, clinician-rated global clinical 
state and activitites of daily living.
In the study by Corey-Bloom et al (1998), participants 
in the high-dose group showed an average decline that was 
3.78 points less than the decline shown by placebo partici-
pants in the ADAS-Cog. The study reported a statistically 
signiﬁ  cant difference on the MMSE between the high-dose 
treatment group and the placebo group with an improve-
ment in the high-dose group of 0.30 points and a decline in 
the placebo participants of –0.79 points. In the CIBIC-Plus, 
the authors reported an average difference of 0.29 points 
between high-dose and placebo participants. In the GDS, 
the high-dose group scores deteriorated by 0.19 points less 
than the placebo group scores. Finally, in the PDS the study 
showed a statistically signiﬁ  cant difference of 3.38 points 
between the 6–12 mg/day rivastigmine participants and the 
placebo group.
The study by Agid et al (1998) compared two ﬁ  xed-dose 
groups (4 and 6 mg/day) with a placebo, and did not report 
any statistically signiﬁ  cant differences between treatment 
and placebo groups for cognitive and functional outcome 
measure. In particular, on the NOSGER scale this study 
compared two different dose treatment groups with placebo. 
No p-values were reported for this outcome measure, but the 
high-dose rivastigmine group (6–12 mg/day) seemed to show 
an average improvement in memory and IADL performance 
(mean differences of –0.2 and –0.5, respectively).
In the study conducted by Forette et al (1999), patients 
taking rivastigmine bid improved more signiﬁ  cantly in the 
CIBIC-Plus assessment of global functioning than those 
taking the placebo. The treatment size was large: 57% 
responders in the rivastigmine bid group vs 16% in the 
placebo group. ADAS-Cog scores also improved in patients 
receiving rivastigmine bid compared with the placebo, but 
just failed to reach statistical signiﬁ  cance (p = 0.054). In 
addition, rivastigmine produced a signiﬁ  cant improvement 
in the memory dimension of the NOSGER. Although this 
study suggests an improvement in global functioning as rated 
by the physician (CIBIC-plus), functioning as assessed by 
psychometric tests (ADAS-Cog), and ADL as assessed by 
the carer (NOSGER), the sample sizes were very small (30 
participants in each group) and no information was presented 
on power calculations.
In the study by Rosler et al (1999), ADAS-Cog improved 
in patients in the higher dose group compared to patients 
taking the placebo (p  0.05). Signiﬁ  cantly more patients 
in the higher dose group improved by 4 points or more than 
those in the placebo group (24% [57/242] vs 16% [39/238]). 
Global functioning as rated by the CIBIC-plus scale sig-
niﬁ  cantly improved among those in the higher dose group 
compared to those taking the placebo (p  0.001), and 
signiﬁ  cantly more patients in the higher dose group showed 
improvement than in the placebo group (37% [80/219] vs 
20% [46/230]). Mean scores on the progressive deterioration 
scale improved from baseline in patients in the higher dose 
group but fell in the placebo group.
On the MMSE, patients receiving the placebo deterio-
rated by 0.47 points from baseline on the MMSE and those 
receiving 6–12 mg/day rivastigmine improved by 0.21 points 
over baseline using the intention to treat analysis. On the 
GDS, signiﬁ  cantly less deterioration occurred in patients 
taking 6–12 mg/day rivastigmine than in those taking the 
placebo.
In summary, statistically signiﬁ  cant differences between 
the 6–12 mg/day treatment groups (mean dose ~10 mg/day) Therapeutics and Clinical Risk Management 2007:3(6) 1118
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Table 2 Randomized controlled trials of rivastigmine
Study Number  of  patients  Time/doses  Results  p-value
      vs  placebo
Corey-Bloom et al   699 (centers: 22)  1.26 weeks  ADAS-Cog  
1998    1–4 mg/day   2.36 (3.13 to –1.59) 
     MMSE 
     –0.34 
     CIBIC-plus 
      0.23 (0.07 to 0.39) 
     GDS 
      –0.16 (–0.25 to –0.07) 
     PDS 
      –5.15 (–6.52 to –3.86) 
    2.26 weeks  ADAS-Cog  
    6–11 mg/day  0.31 (1.08 to –0.46)  0.001
     MMSE 
     0.30 0.05
     CIBIC-plus 
     0.20  (0.04–0.36)  0.01
     GDS 
      –0.13 (–0.22 to –0.04)  0.03
     PDS 
      –1.52 (–2.85 to –0.19)  0.001
    3.26 weeks  ADAS-Cog  
   placebo  4.09  (4.86–3.32) 
     MMSE 
     –  0.79 
     CIBIC-plus 
     0.49  (0.33–0.65) 
     GDS 
      –0.32 (–0.41 to –0.23) 
     PDS 
      –4.90 (–6.22 to –3.58) 
Agid et al 1998  402 (centers: 54)  13 weeks  MMSE 
    4 mg/day   0.0 ± 3.3 
     NOSGER  (memory) 
     0.7  ± 2.8 
     NOSGER  (IADL) 
     0.0  ± 3.3 
    13 weeks  MMSE  Not reported
   6  mg/day  0.3  ± 3.1 
     NOSGER  (memory) 
     0.2  ± 2.4 
     NOSGER  (IADL) 
     –0.7  ± 3.5 
   13  weeks  MMSE 
   placebo    –0.0  ± 2.6 
     NOSGER  (memory) 
     0.0  ± 3.4 
     NOSGER  (IADL) 
     –0.2  ± 3.3 
Forette et al 1999   114 (centers: 11)  18 weeks  ADAS-Cog   NS (0.054)
   twice/daily  –2.6   
    mean dose  NOSGER (memory)  0.037
   9.6  mg/day  –0.7  ± 2.9 
    18 weeks  ADAS-Cog   NS
    3 times/daily  0.41  
    mean dose  NOSGER (memory)  0.014
   10.1  mg/day  –1.0  ± 2.7 
(Continued)Therapeutics and Clinical Risk Management 2007:3(6) 1119
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and the placebo participants were reported in two of three 
published trials on ADAS-Cog and MMSE. In these studies, no 
statistically signiﬁ  cant effects were seen in the low-dose treat-
ment groups. Both of the published studies (Corey-Bloom et al 
1998; Rosler et al 1999) that included CIBIC-plus as a global 
outcome measure reported statistically signiﬁ  cant improve-
ment in high-dose participants (6–12 mg/day) compared 
with placebo participants. One study reported that a higher 
proportion of high-dose rivastigmine participants than placebo 
participants had a “successful” CIBIC assessment, ie, obtaining 
a score of 1 or 2 on the scale. The same trials (Corey-Bloom 
et al 1998; Rosler et al 1999) found a statistically signiﬁ  cant 
improvement on the GDS measure in participants treated 
with 6–12 mg/day of rivastigmine compared with placebo 
participants. These studies reported the PDS as a functional 
outcome measure. One of these found a statistically signiﬁ  -
cant improvement in participants treated with 6–12 mg/day 
rivastigmine compared with participants taking a placebo, 
and the other reported that a statistically signiﬁ  cantly higher 
percentage of these high-dose participants, but not placebo 
participants, showed an improvement of at least 10%.
Long-term therapy
Additional evidence is available from studies that were not 
randomized and double blind, open label extension studies. 
These studies recruit patients who have been participating 
in a phase III, randomized, double-blind, placebo-controlled 
study to continue on open label treatment (Table 3). 
Table 2 (Continued)
Study Number  of  patients  Time/doses  Results  p-value
      vs  placebo
    18 weeks  ADAS-Cog  
   placebo  2.0 
     NOSGER  (memory) 
     1.3  ± 3.7 
Rosler et al 1999   725 (centers: 22)  26 weeks  ADAS-Cog  
    1–4 mg/day   1.37 (2.27–0.53) 
     MMSE   
      –0.62 (–1.05 to –0.15) 
     CIBIC-plus 
     4.24  (4.02–4.38) 
     GDS 
      –0.22 (–0.3 to –0.1) 
     PDS 
      –3.37 (–4.99 to –1.61) 
    26 weeks  ADAS-Cog   0.011
    6–11 mg/day  –0.26 (0.66 to –1.06) 
     MMSE    0.05
      0.21 (–0.24 to 0.64) 
     CIBIC-plus  0.001
     3.91  (3.71–4.09) 
     GDS 0.05
      –0.06 (–0.2 to –0.0) 
     PDS  0.07
      0.05 (–1.57 to 1.77) 
    26 weeks   ADAS-Cog  
   placebo  1.34  (2.19–0.41) 
     MMSE   
      –0.47 (–0.96 to –0.04) 
     CIBIC-plus 
     4.38  (4.22–4.58) 
     GDS 
      –0.26 (–0.4 to –0.2) 
     PDS 
      –2.18 (–3.91 to –0.49) 
Derived from Loveman et al (2006).
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale Cognitive Subscale; CIBIC-plus, Clinical Rating and Clinician’s Interview-Based Impression of Change 
Plus Caregiver Input; GDS, Global Deterioration Scale; IADL, Instrumental Activities of Daily Living; MMSE, Mini Mental Status Examination; NOSGER, Nurses’ Observation 
Scale for Geriatric Patients; PDS, Progressive Deterioration Scale.Therapeutics and Clinical Risk Management 2007:3(6) 1120
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Farlow et al (2000) reported the results of a 52-week 
“delayed start” rivastigmine study in mild to moderate 
AD. For the ﬁ  rst 26 weeks, patients received a placebo 
or rivastigmine. All patients were then eligible to receive 
open-label rivastigmine for another 26 weeks. On ADAS-
Cog, there was a signiﬁ  cant, 5.7-point treatment difference 
for patients who remained on rivastigmine for 52 weeks 
(p  0.001) compared with the projected decline if they 
were left “untreated”, calculated by using a statistical 
model. In addition, patients who received a placebo for the 
ﬁ  rst 26 weeks and were then switched to rivastigmine for 
weeks 27–52 did not “catch up” with those who had been 
on rivastigmine from the beginning of the trial (1.4-point 
difference on ADAS-Cog).
The effects of rivastigmine on cognition were shown to 
persist for up to 2 years in a meta-analysis of 2010 patients 
with AD who took part in four, 26-week, placebo-controlled 
studies followed by open-label extensions (Grossberg et al 
2004). Patients remaining on rivastigmine for up to 2 years 
showed 4–5 points less decline on ADAS-Cog compared 
with the projected decline if they were left “untreated”. These 
conclusions are based on a comparison of the actual clinical 
changes measured in patients treated with rivastigmine in 
open-label studies, with hypothetical clinical changes derived 
by predicting the scores of those same patients had they been 
left untreated, using a baseline-dependent model derived from 
data in an untreated AD population (Grossberg et al 2004).
More recently, this meta-analysis (Grossberg et al 2004) 
was “updated”, with patients remaining on treatment for up 
to 5 years (Small et al 2005). These data provide the longest-
term efﬁ  cacy data for any ChE-I to date. Even though only 
83 patients remained under study conditions at 5 years, these 
data can be considered informative because most patients 
tend to discontinue ChE-I treatment over time (Bullock 
et al 2005). Mean baseline MMSE and ADAS-Cog scores at 
entry into the placebo-controlled studies were 19.3 and 24.6, 
respectively. Mean MMSE and ADAS-Cog scores of patients 
remaining on rivastigmine for 5 years were 12.7 and 36.8 
(both showing “moderate” AD) (Small et al 2005). Patients 
remaining on rivastigmine for 5 years on average declined 
1.7 points each year on the MMSE, or 3.9 points each year 
on ADAS-Cog. These cognitive declines were smaller 
than those predicted using baseline-dependent models of 
“untreated” patients and smaller than those reported for 
untreated patients in the literature (Bullock et al 2005).
Head-to-head drug comparisons
Three randomized studies were designed to compare two 
ChE-Is, donepezil and rivastigmine (Fuschillo et al 2001; 
Wilkinson et al 2002; Bullock et al 2005).
Table 3 Long term studies of rivastigmine
Study Time  Study  design  Objectives
Farlow et al 2000  1-year data   26-week open-label extension of  ADAS-Cog: signiﬁ  cant 5.7-point 
    a 26-week, placebo-controlled  improvement compared with the 
   study  (n  = 533)  projected placebo
      decline at 52 weeks (the end of the
     open-label  extension)
Grossberg et al 2004  2-year data  Meta-analysis of two open-label  ADAS-Cog: declined by 4–5 
    continuations of four placebo   points less than
    controlled studies, total duration  predicted, had patients been left 
    104 weeks (n = 2010) “untreated”
Small et al 2005  5-year data  Meta-analysis of two open-label  ADAS-Cog: mean annual decline 
    continuations of four placebo   of 3.9 points; patients remaining 
    controlled studies, maximum total  on rivastigmine for 5 years 
    duration 260 weeks (n = 2010)  declined by about 20 points less 
      than predicted for model-based 
     “untreated”  patients
      MMSE: mean annual decline of 
      1.7 points; patients remaining on 
      rivastigmine for 5 years
      declined by 7 points less than 
     predicted  for 
     model-based  “untreated”  patients
Derived from Bullock et al (2005).
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale Cognitive Subscale; MMSE, Mini Mental Status Examination.Therapeutics and Clinical Risk Management 2007:3(6) 1121
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In the Fuschillo et al (2001) single-center study of only 
27 participants, those in the donepezil group were given 
5 mg/day and those in the rivastigmine group 1.5 mg/day 
for 1 week, increasing weekly in steps of 1.5 mg up to 
6–9 mg/day; treatment duration was 30 weeks.
In the Wilkinson et al (2002) study, those in the donepezil 
arm were given 5 mg/day for 28 days followed by 10 mg/day; 
those in the rivastigmine arm were initially given 1.5 mg 
twice daily for 14 days, then 3 mg twice daily for 14 days, 
then 4.5 mg twice daily for 14 days and ﬁ  nally, if tolerated, 
6 mg twice daily. The study was a multi-center, open label 
study (19 centers) with 112 participants who knew which 
drug they were taking; treatment duration was 12 weeks.
On measures of cognitive ability, both studies reported 
that treatment with rivastigmine (1.5–12 mg/day) led to 
greater improvement than treatment with 5 mg/day done-
pezil; however, these trends were small, were not tested for 
statistical signiﬁ  cance, and could also reﬂ  ect differences in 
the doses given. Rates of adverse events tended to be higher 
in the rivastigmine group than in the donepezil group, and 
more participants withdrew owing to adverse events in the 
rivastigmine groups. The effects of the doses reported may 
reﬂ  ect these differences.
Recently, Bullock et al (2005) designed a double-blind, 
randomized, controlled, multi-center international trial to 
evaluate the efﬁ  cacy and tolerability of ChE-I treatment in 
patients with moderate to moderately severe AD over a 2-year 
period. The randomized number was 994. The titration period 
was 16 weeks. The rivastigmine group started at 3 mg/day, 
and the dose was increased by 3 mg/day at 4-week intervals 
until a maximum of 12 mg/day was reached. The donepezil 
group received 5 mg/day in weeks 1–8 and 10 mg/day 
thereafter. Following the 16-week titration, patients were 
maintained at the highest tolerated dose level. The study 
showed that ChE-I treatment may offer continued therapeutic 
beneﬁ  t for years in patients with moderate AD and, although 
both drugs had the same effect on cognition and behavior, 
rivastigmine may provide greater beneﬁ  ts in activities of 
daily living and global functioning.
Conclusions
Rivastigmine has been shown effective and safe in the treat-
ment of the cognitive, behavioral, and functional deﬁ  cits of 
AD (Birks et al 2002). RCT studies have demonstrated a 
statistically signiﬁ  cant difference between drug and placebo 
on neuropsychological scales, clinician-rated global clinical 
state and activities of daily living. Although these ChE-I 
have been approved by the FDA for the treatment of mild to 
moderate AD, there are still doubts about their actual efﬁ  -
cacy and many problems still exist regarding the transfer of 
information from an experimental setting to clinical practice 
(Schneider 2006).
The National Institute for Clinical Excellence (NICE 
2001) (www.nice.org.uk) appraised these drugs in 2000 and 
endorsed their use provided a number of conditions were 
met. Treatment guidelines recommend that ChE-I treat-
ment should be continued only if there is an increase, or no 
decrease, in the MMSE score 2–4 months after reaching the 
suitable dose.
The guidelines for clinical practice (Davies and Maloney 
1976; Doody et al 2001; Caltagirone et al 2005) have derived 
treatment indications from RCTs. One limitation of RCTs on 
AD is the long disease duration (years) compared with the 
short duration of clinical trials (weeks), which could impede 
obtaining long-term information on treatment effects.
Moreover, RCTs’ end-point estimates are surrogate end-
points (eg, the ADAS-Cog cognitive improvement of 3–6 
months) considered as valid substitutes of real end points 
(eg, to stabilize or totally improve functions of the affected 
subject in the long term). Still, in randomized clinical studies 
the effect of this variability, analogous to misclassiﬁ  cation 
of exposition and/or disease in the case of control or cohort 
epidemiological studies, is that of underestimating the true 
efﬁ  cacy of interventions.
Moreover, the beneﬁ  ts from this drug are limited and its 
long-term effectiveness has not been well demonstrated. In 
fact, as AD generally progresses slowly and a clinical course 
of 5–10 years is not unusual, clinical trials involving 6 or 
12 months of treatment are of limited use. Unfortunately, 
randomized trial evidence of longer-term effects is not 
currently available and, given the widely differing rates of 
progression of AD in different individuals and in groups 
selected in different ways, extrapolation could be misleading. 
There are reports of open-label extensions to some of the 
included studies. Data suggest that patients who remained 
on rivastigmine for up to 5 years showed a smaller decline 
on cognitive aspects compared with the projected decline 
had they been left untreated. The results of open-label exten-
sion trials should be interpreted with caution. In fact, there 
may be several reasons for bias: not all patients participate 
in the extensions of the trials, only a self-selected group; 
comparisons are made using historical controls or a hypo-
thetical placebo decline obtained by extrapolation from the 
randomized phase. Although these preliminary data suggest a 
reduction in AD progression, there is a need for randomized, 
placebo-controlled trials of longer than one year to establish Therapeutics and Clinical Risk Management 2007:3(6) 1122
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the beneﬁ  ts of these drugs in the long term; at the moment, 
in fact, only one study spanned a 5-year period.
The issue regarding duration of treatment and criteria of 
suspension is still unresolved, and further studies are needed 
to help establish the maximum duration of treatment and 
the indicators that could show when treatment is no longer 
beneﬁ  cial. Nevertheless, new data suggest that cholinesterase 
inhibition may continue for up to 5 years.
Another unsolved and frequent problem is the decision 
about which ChE-I to use. Existing trials indicate no major 
differences in efﬁ  cacy between rivastigmine and the other 
ChE-Is. Very recently, the Cochrane Collaboration (Birks 2006) 
conﬁ  rmed the positive effect of donepezil, galantamine, and 
rivastigmine in people with mild, moderate, or severe dementia 
due to AD without indicating any signiﬁ  cant differences among 
the ChE-Is for improving cognition and global status.
In fact, head-to-head, rivastigmine vs donepezil trials are 
limited; thus no guidelines for clinical treatment are provided 
(Bullock et al 2005). Both drugs performed the same way on 
cognition and behavior, but rivastigmine seemed to improve 
ADL and global functioning even though there were some 
differences in the doses given (Wilkinson et al 2002).
Nevertheless, previous ﬁ  ndings (Gauthier et al 2006) 
support the hypothesis that many patients failing to respond 
to ChE-selective inhibitors may beneﬁ  t from being switched 
to rivastigmine and that patients unable to respond adequately 
to any ChE-I may obtain cognitive beneﬁ  ts from concomitant 
therapy with memantine. A recently published, open-label 
study evaluated the efﬁ  cacy of the ChE-I rivastigmine on 
cognition, functional autonomy, and behavior in patients with 
mild to moderate AD previously treated with other ChE-Is 
(switched patients). The authors concluded that patients 
switched from previous ChE-I therapy to rivastigmine can 
obtain measurable beneﬁ  ts, but the treatment effect may be 
less than in de novo patients (Dantoine et al 2006).
In conclusion, a number of large, placebo-controlled, 
double-blind trials have demonstrated that the use of 
rivastigmine results in signiﬁ  cant improvements in cognitive, 
functional and global performances of AD patients (Birks 
et al 2002). Preliminary evidence also indicates the poten-
tial efﬁ  cacy of this drug in the treatment of behavioral and 
psychiatric symptoms and disturbances (Weinstock 1999; 
Minger et al 2000; Giacobini 2000).
Despite evidence from clinical studies and intervening 
clinical experience, the debate continues about whether 
ChE-Is are effective; in particular, information regarding their 
impact on quality of life and cost-effectiveness is lacking, 
resulting in some uncertainty about the guidance provided.
It is important for patients and caregivers to understand 
that they should not expect increasing improvements long 
term; indeed, the aim should be to maintain patients’ status 
at a manageable level, and to make it possible for patients 
to continue to be themselves.
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